The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Lyell Immunopharma's Cash Ratio for the quarter that ended in Dec. 2023 was 15.82.
Lyell Immunopharma has a Cash Ratio of 15.82. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Lyell Immunopharma's Cash Ratio or its related term are showing as below:
LYEL'
s Cash Ratio Range Over the Past 10 Years
Min: 12.43 Med: 15.82 Max: 19.78
Current: 15.82
During the past 5 years, Lyell Immunopharma's highest Cash Ratio was 19.78. The lowest was 12.43. And the median was 15.82.
LYEL's Cash Ratio is ranked better than 91.08% of 1525
companies
in the Biotechnology industry
Industry Median: 2.97
vs LYEL: 15.82
Lyell Immunopharma Cash Ratio Historical Data
The historical data trend for Lyell Immunopharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Lyell Immunopharma Annual Data
Trend
Dec19
Dec20
Dec21
Dec22
Dec23
Cash Ratio
19.78
12.43
13.15
17.29
15.82
Lyell Immunopharma Quarterly Data
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Cash Ratio
17.29
19.90
17.32
16.41
15.82
Competitive Comparison
For the Biotechnology subindustry, Lyell Immunopharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyell Immunopharma Cash Ratio Distribution
For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Lyell Immunopharma's Cash Ratio falls into.
Lyell Immunopharma Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Lyell Immunopharma's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyell Immunopharma (NAS:LYEL) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Lyell Immunopharma Cash Ratio Related Terms
Thank you for viewing the detailed overview of Lyell Immunopharma's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Lyell Immunopharma (Lyell Immunopharma) Business Description
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LYEL has been successfully added to your 